Related Experiment Video
Updated: Jul 7, 2025
Expression of Exogenous Cytokine in Patient-derived Xenografts via Injection with a Cytokine-transduced Stromal Cell Line
Published on: May 10, 2017
Aberrant myelomonocytic CD56 expression predicts response to cyclosporine therapy in pediatric patients with moderate
Shanshan Qi1, Yu Du2, Ming Sun1
1Laboratory of Pediatric Hematology, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Insights
Neural cell adhesion molecule-positive (CD56+) myelomonocytes indicate a better prognosis in pediatric moderate aplastic anemia. These CD56+ cells are associated with increased myeloid cells and improved response to cyclosporine therapy.
Area of Science:
- Hematology
- Immunology
- Pediatric Oncology
Background:
- Aplastic anemia (AA) is a rare bone marrow failure disorder.
- Moderate aplastic anemia (mAA) requires understanding prognostic markers for effective treatment.
- Neural cell adhesion molecule (CD56) expression on myeloid cells is not well-characterized in pediatric mAA.
Purpose of the Study:
- To investigate the expression patterns of CD56+ myelomonocytes in pediatric mAA.
- To determine the clinical significance and prognostic value of CD56+ myelomonocytes.
- To evaluate the association between CD56 expression and response to cyclosporine therapy.
Main Methods:
- Flow cytometry was used to detect CD56 expression on myelomonocytes in 56 pediatric mAA patients.
- Clinical data, laboratory results, and cyclosporine response were collected.
- Multivariate analysis assessed the link between CD56 expression and treatment outcomes.
Main Results:
- CD56+ myelomonocytes were found in 43% of pediatric mAA cases.
- Aberrant CD56 expression was observed on immature granulocytes and mature monocytes.
- CD56+ patients showed a distinct bone marrow profile, including more myeloid cells and fewer lymphocytes, and a favorable response to cyclosporine.
Conclusions:
- CD56+ myelomonocytes are associated with an increased myeloid compartment and better prognosis in pediatric mAA.
- The presence of CD56+ myelomonocytes is a favorable factor for cyclosporine response at 6 months.
- CD56+ myelomonocytes play a beneficial role in the progression of aplastic anemia.
Objects:
This study aimed to investigate the expression patterns and clinical significance of neural cell adhesion molecule-positive (CD56+) myelomonocytes in pediatric patients with moderate aplastic anemia (mAA).
Methods:
Fifty-six pediatric patients with mAA were enrolled in this study. The patients' clinical characteristics, laboratory data, and response to cyclosporine therapy were obtained. CD56 expression on bone marrow myelomonocytic cells was investigated using flow cytometry. The association between aberrant CD56 expression and cyclosporine response was evaluated by a multivariate analysis.
Results:
CD56+ myelomonocytes were detected in 43% of the mAA cases. Aberrant CD56 expression was frequent on immature CD45dimCD16dim granulocytes and mature CD45brightCD14bright monocytes. Compared with patients with CD56- myelomonocytes (CD56- patients), patients with CD56+ myelomonocytes (CD56+ patients) were in moderate hematological condition and had a distinct bone marrow cellular composition profile, which included an increased proportion of myeloid cells and CD56bright natural killer cells and a reduced proportion of CD4+ T cells, CD8+ T cells, and B cells. The multivariate analysis determined that CD56+ myelomonocytes were a favorable factor for achieving response at 6 months after cyclosporine therapy. There was a trend towards a lower 3-year rate of evolution to severe aplastic anemia or relapse among the CD56+ patients (8%) than the CD56- patients (22%).
Conclusion:
CD56+ patients had an increased myeloid compartment and better prognosis compared with CD56- patients. The findings demonstrated the favorable role of CD56+ myelomonocytes in aplastic anemia progression.
More Related Videos
11:55Induction of Alloantigen-specific Anergy in Human Peripheral Blood Mononuclear Cells by Alloantigen Stimulation with Co-stimulatory Signal Blockade
Published on: March 14, 2011
08:17A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
Published on: August 15, 2019
